KAYTUS
21.5.2024 12:18:30 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, introduced at ISC High Performance 2024 its high-density computing server KR1280V2. It supports 32 E1.S SSDs, achieving an impressive flash memory density of 512TB in a 1U form factor. Compared to the last generation, KR1280V2 adopts low latency storage and network design, doubling the high concurrency I/O performance for LLM training scenarios, and improving model training efficiency.
This 1U2S flagship server is powered by the latest Intel, AMD, or ARM processors. The KR1280V2 features an optimized cooling strategy to support CPUs with the highest TDP across platforms, without configuration restrictions. It also introduces a novel front I/O configuration, enhancing scalability with 8 PCIe 5.0 expansion cards and improving maintenance efficiency in data centers. The server’s drive tray type has been optimized to offer an innovative storage configuration of 12 front SFF drives, increasing storage density by 20%.
Supports 32 E1.S SSDs without performance degradation, delivering tens of millions IOPS
Powered by 5th Gen Intel® Xeon® processors and boasting remarkable computing density, the KR1280V2 supports up to 32 all-flash E1.S SSDs directly connected to CPUs within a 1U form factor. This configuration harnesses the full I/O rate of PCIe 5.0, maximizing throughput between CPUs and storage, achieving up to 160GB/s storage throughput. With load balancing across two OCP 3.0 cards, it doubles network bandwidth, catering to diverse data storage and processing needs while enhancing overall computing performance by 60%.
With ultimate flash memory density, the KR1280V2 effectively doubles LLMs' high concurrency performance
The KR1280V2 achieves tens of millions of IOPS performance in distributed storage scenarios, marking a remarkable 77% improvement. Deploying KR1280V2 servers for large-scale LLMs training ensures a twofold increase in high-concurrency I/O performance compared to the previous generation. As the number of GPUs and workload increases, the KR1280V2's latency curve becomes smoother and more predictable, demonstrating a notable 13% improvement in data latency also compared to the prior generation. These significant advancements enhance data preparation efficiency, model training, and data management while reducing wasted storage space. Consequently, it delivers robust storage capacity and performance for innovative LLM applications and better supports Java-based business scenarios requiring massive data, low latency, and high concurrency, such as in finance, cloud services, enterprises, and other data center applications.
Optimized cooling technologies and exceptional business reliability and sustainability
In terms of heat dissipation, the KR1280V2 supports multiple cooling methods, including EVAC heatsink air cooling, cold-plated liquid cooling, and single-phase immersion liquid cooling. It achieves an 8% to 12% power reduction through fan partition regulation, one-click BIOS optimization, and other techniques across 17 energy-efficient scenarios. Additionally, the KR1280V2 employs numerous advanced technologies to enhance stability and security. It introduces the exceptional MUPR2.0 early detection memory fault function, which utilizes a more comprehensive memory scrubbing technique to self-check and fix memory faults, achieving a broader range of error correction and a higher level of system protection. Consequently, the system's downtime rate is 69% lower than the industry average.
To learn more about the KAYTUS KR1280V2 high-density server, please visit the website.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521588996/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom